Last week, the impending merger of Pfizer and Wyeth sparked some very interesting dialogue, with voices for and against the fusion of a new pharmaceutical giant.
There was a quite a bit of negative opinion against further M&A activity in the sector. It seems that less time is spent on the positive side - what strategic decisions would
you see as valuable? After all, if CI is looking to increase its value in the organization, we might do well to present opportunities for business development alongside any information on threats we must broadcast. A spoonful of sugar makes the medicine go down.
So here's my positive take. I'd love to see companies:
- Admitting that giant R&D is insufficiently productive, and working to leverage Open Source research business models
- Basing its future business model around the fact that the U.S. private healthcare system is going to fold in the next few years, and thinking up innovative pricing models
- Focusing on deep expertise in certain diseases, especially chronic disease
- Pioneering new ways to relate to doctors, accepting that the sales rep/advertising model is close to extinct
Maybe the broad, department store approach to pharma will work out. But I'd especially like to hear companies talk about how the future will affect their strategy.
What would you like to hear?